SMI, CH0009980894

SMI falls 1.10% as Novartis update weighs on Swiss equities

Published on 11/19/2026 at 22:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The SMI fell 1.10% to 14,721.84 points on Thursday, extending its decline for a third consecutive session. Novartis was among the main drags after updating its medium-term sales-growth guidance.

Swiss equities retreat on Thursday

  • The SMI ended 1.10% lower at 14,721.84 points on November 19, 2026.
  • Novartis fell after lowering its medium-term sales-growth outlook to 5% annually through 2031 at constant exchange rates.
  • All nine European indexes tracked by The Edge ended lower, with healthcare among the weakest sectors.
SMI, CH0009980894, Illustration mit AI erstellt.

Swiss equities ended Thursday under pressure as the SMI fell 164.28 points, or 1.10%, to 14,721.84 points. The index finished at the session low after opening almost unchanged at 14,889.47 points, following Wednesday's close of 14,886.12 points.

The closing figures and the session range were reported by Finanznachrichten.de, citing dpa-AFX. The report said the SMI spent only a few minutes above the flat line after the opening bell before retreating through the session.

Novartis guidance weighs on sentiment

Novartis declined 3.2% after updating its medium-term outlook. The pharmaceutical group now expects net sales to grow at a compound annual rate of 5% from 2026 through 2031 on a foreign-exchange-adjusted basis. The revised target was below the 5% to 6% annual growth range previously set for 2025 through 2030, according to the market report.

Other major decliners included Schindler, down 4.1%, and Lindt & Spruengli, down 3%. Nestle, Sika, Swisscom, Galderma Group and Swiss Re lost between 1.4% and 1.9%. Zurich Insurance, Helvetia Baloise and Roche also finished lower. Alcon gained 1.6%, while Richemont, Sonova and Logitech International rose by nearly 1%.

European markets finish broadly lower

The broader European backdrop was also weak. The Edge reported that all nine European indexes in its closing table ended lower for a third consecutive session. The SMI recorded the largest decline in that group, while the Stoxx Europe 600 lost 0.88%. Healthcare was the weakest of the tracked sectors, down 1.79%, as technology's early rebound faded to a 0.01% decline.

Market sentiment was initially supported by enthusiasm surrounding Anthropic's record initial public offering, but that buoyancy faded during the session. The dpa-AFX report also pointed to rising geopolitical tensions as investors became more cautious. Swiss economic data provided a mixed backdrop: the October trade surplus widened to CHF 3.2 billion from CHF 1.2 billion in September, while third-quarter industrial production growth slowed sharply year over year.

SMI remains Switzerland's blue-chip benchmark

The SMI is the benchmark for Switzerland's blue-chip equity market. According to SIX, it comprises the 20 largest and most liquid equities from the SPI and represents approximately 75% of Swiss equity-market capitalization.

More coverage is available on the SMI topic page

Disclaimer...
en | CH0009980894 | SMI | boerse | 70538111 | bgmi